
    
      Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD,
      immunogenicity and preliminary antitumor activity of IBI322 in China. Phase 1a is dose
      escalation and plans to enroll approximately 39-102 subjects with hematologic malignancy who
      failed the standard treatment. Phase 1b is dose expansion, and plans to enroll approximately
      80 subjects with hematologic malignancy.
    
  